Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Lara Naletto"'
Autor:
Letizia Canu, Clotilde Sparano, Lara Naletto, Giuseppina De Filpo, Giulia Cantini, Elena Rapizzi, Serena Martinelli, Tonino Ercolino, Francesca Cioppi, Alessandro Fantoni, Lorenzo Zanatta, Alessandro Terreni, Massimo Mannelli, Michaela Luconi, Mario Maggi, Francesco Lotti
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2024)
PurposeAdrenocortical carcinoma (ACC) is a rare and aggressive tumor. ACC male patients under adjuvant mitotane therapy (AMT) frequently develop hypogonadism, however sexual function has never been assessed in this setting. The aim of this retrospect
Externí odkaz:
https://doaj.org/article/c80ae0ff8c364ee99c9961898ea05a70
Publikováno v:
Endocrine. 74(3)
The aim of the present network meta-analysis is to assess the efficacy and safety across different long and short-acting analogs for the treatment of type 2 diabetes. A PubMed, EMBASE, and Cochrane Central Register of Controlled Trials databases sear
Autor:
Gabriele Vaccaro, Ilaria Dicembrini, Edoardo Mannucci, Matteo Monami, Lara Naletto, Antonio Silverii, Basilio Pintaudi
Publikováno v:
Nutrition, metabolism, and cardiovascular diseases : NMCD. 31(4)
Aim Aim of the present network meta-analysis (NMA) is the comparison across glucose-lowering drugs (GLA) concerning their effects on glucose control, body weight, hypoglycemia, gastrointestinal adverse events, and quality of life. Data synthesis This
Publikováno v:
SSRN Electronic Journal.
Background: Immune checkpoint inhibitors (ICI) exert their therapeutic effect by modulating the immune system and potentiating antitumor immune. ICI have been associated to several immune-related adverse events, such as diabetes. However, no formal m
Autor:
Diego Faggian, Jacopo Manso, Bernard Rees Smith, Marco Boscaro, Chiara Sabbadin, Jadwiga Furmaniak, Simona Censi, Mario Plebani, Shu Chen, F. Presotto, Miriam Dalla Costa, Carla Scaroni, Filippo Ceccato, Riccardo Scarpa, Anna Chiara Frigo, Stefano Masiero, Corrado Betterle, Francesca Pigliaru, Lara Naletto
Publikováno v:
European journal of endocrinology. 180(3)
Background Adrenal cortex autoantibodies (ACAs) and/or 21-hydroxylase (21OHAb) are markers of autoimmune Addison’s disease (AAD) and progression to overt AAD. The reported cumulative risk of developing AAD varies from 0 to 90% in different studies.